相关实验视频

Updated: Jun 6, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

埃索梅普拉对患有外周纤维化病的老鼠的抗纤维作用

Ali Borekci¹, Pinar Kuru Bektasoglu¹, Adnan Somay²

¹University of Health Sciences, Fatih Sultan Mehmet Education and Research Hospital, Department of Neurosurgery, Istanbul, Turkiye.

Global spine journal

|December 2, 2024

概括

埃索梅普拉在小鼠的拉美切除术后有效降低了外周纤维化. 这种药物的局部和全身治疗都能最大限度地减少痕厚度,为预防术后并发症提供了潜在的好处.

科学领域:

神经外科神经外科
药理学药理学是指药理学的学科.
组织病理学组织病理学

背景情况:

过度的痕形成术后可以导致神经陷和疼痛.
脊柱纤维化是脊柱手术后的一个严重并发症.
目前预防外周膜纤维化的治疗方法有限.

研究的目的:

调查埃索梅普拉在拉美切除术后预防外周纤维化后的疗效.
为了比较局部和全身服用埃索梅普拉的效果.
为了评估埃索梅普拉对痕形成的影响,在老鼠细膜切除模型中.

主要方法:

采用了一种老鼠膜切除模型.
鼠被分为对照组,局部以索梅普拉和系统性以索梅普拉组.
手术后四周进行了宏观和组织病理学检查.

主要成果:

与对照组相比,系统性埃索梅普拉显著降低了宏观外周膜纤维化得分 (P < 0.001).
局部和全身埃索梅普拉都显著降低了纤维化厚度 (P < 0.01,P < 0.001).
显微纤维化得分和纤维细胞密度在治疗组和对照组之间没有显著差异.

结论:

埃索梅普拉显示出在拉米切除术后减少外周纤维化形成的潜力.
局部和全身管理都有效降低纤维化厚度.
进一步的研究可能会探索埃索梅普拉作为一种治疗药物,用于预防拉米切除术后的并发症.

关键词:

脊髓外膜纤维化脊髓外膜纤维化埃索梅普拉 (esomeprazole) 是一种药物.拉米切除术 (laminectomy) 是一种切除膜的方法.根本性疼痛是一种根性疼痛.

更多相关视频

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Published on: March 19, 2018

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...